Attached files
file | filename |
---|---|
EX-32.1 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli-2017033110qex321.htm |
EX-31.2 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli-2017033110qex312.htm |
EX-31.1 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli-2017033110qex311.htm |
EX-10.3 - THIRD AMENDMENT TO LEASE AGREEMENT - PDL BIOPHARMA, INC. | pdli-2017033110qex103.htm |
EX-10.2 - 2017/21 LONG-TERM INCENTIVE PLAN - PDL BIOPHARMA, INC. | pdli-2017033110qex102.htm |
EX-10.1 - 2017 ANNUAL BONUS PLAN - PDL BIOPHARMA, INC. | pdli-2017033110qex101.htm |
10-Q - 10-Q - PDL BIOPHARMA, INC. | pdli-2017033110qdoc.htm |
Exhibit 12.1
PDL BIOPHARMA, INC.
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Unaudited)
(Amount in thousands, except for ratios)
For the Three Months Ended March 31, 2017 | ||||||||||||||||||||||||
2012 | 2013 | 2014 | 2015 | 2016 | ||||||||||||||||||||
Earnings: | ||||||||||||||||||||||||
Income before income taxes | $ | 327,133 | $ | 401,876 | $ | 501,272 | $ | 530,138 | $ | 106,670 | $ | 13,746 | ||||||||||||
Add: fixed charges | 29,097 | 24,931 | 39,274 | 27,123 | 18,330 | 4,995 | ||||||||||||||||||
Earnings | $ | 356,230 | $ | 426,807 | $ | 540,546 | $ | 557,261 | $ | 125,000 | $ | 18,741 | ||||||||||||
Fixed Charges: | ||||||||||||||||||||||||
Interest expense1 | $ | 29,036 | $ | 24,871 | $ | 39,211 | $ | 27,059 | $ | 18,267 | $ | 4,971 | ||||||||||||
Estimated interest portion of rent expense2 | 61 | 60 | 63 | 64 | 63 | 24 | ||||||||||||||||||
Fixed charges | 29,097 | $ | 24,931 | $ | 39,274 | $ | 27,123 | $ | 18,330 | $ | 4,995 | |||||||||||||
Ratio of earnings to fixed charges | 12.24 | 17.12 | 13.76 | 20.55 | 6.82 | 3.75 |
_____________________________________
1 Interest expense includes amortization of debt discount and expenses.
2 Represents the estimated portion of operating lease rental expense that is considered by us to be representative of interest and amortization of discount related to indebtedness.